Skip Navigation

QJM 2006 99(5):350-351; doi:10.1093/qjmed/hcl046
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hughes, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hughes, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Correspondence

Orphan drugs revisited: author's response

The first 10% of the full text of this article appears below.

Sir,

McCabe and colleagues1 discuss what they consider to be a range of inaccuracies in our article on the funding of drugs for exceptionally rare diseases.2 However, we may in fact be singing from a similar hymn sheet.

Where we differ from McCabe et al.13 is in offering practical solutions. Their strict efficiency stance . . . [Full Text of this Article]

D. Hughes

Centre for Economics and Policy in Health Institute of Medical and Social Care Research University of Wales Bangor

email: d.a.hughes@bangor.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?